HSPC: Navigating Risk and Management
Balancing risk, patient quality of life, and treatment impact can be challenging when managing hormone-sensitive prostate cancer (HSPC). How can we apply the growing evidence on progression risk stratification in HSPC, and harness the strength of multidisciplinary teams, to help optimize care?
This Learning Zone will provide an overview of HSPC and progression, with insights from prostate cancer experts discussing these key questions in interviews, a panel discussion, and a podcast series.
Further resources will be added over the next 12 months. You can check back here to:
- Read a comprehensive overview of prostate cancer pathophysiology and disease states, including HSPC and castration-resistant prostate cancer (CRPC)
- Understand different approaches for identifying progression risk in people with HSPC
- Evaluate the role of biochemical recurrence risk (BCR) in predicting further disease progression and influencing management decisions
- Stay up to date with the latest management and communication approaches being adopted by multidisciplinary teams in prostate cancer
of interest
are looking at
saved
next event
This educational program has been developed by EPG Health in partnership with the sponsor, Astellas. Indications and availability of products discussed in this educational program may vary in different countries. Please refer to the local summary of product characteristics / prescribing information for details. Astellas prohibits the promotion of unapproved uses and complies with all applicable laws, regulations, and company policies. In expert interviews, podcasts, and panel discussions, the views, thoughts, and opinions expressed belong solely to the speaker(s) and are subject to change without notice. This content is intended for healthcare professionals (HCPs) only. Non-HCPs should not view this educational program and should exit the program as soon as possible.
MA-MM-14197, March 2025.